MRM Health and IFF Reach Second Milestone in the partnered Type 2 Diabetes program

MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has  achieved preclinical development targets.